Treatment of group I pulmonary arterial hypertension with carvedilol is safe

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 12, 2014, Pages 1562-1564

  Grinnan, Daniel ^a   Bogaard, Harm Jan ^b   Grizzard, John ^a   Van Tassell, Benjamin ^a   Abbate, Antonio ^a   DeWilde, Christine ^a   Priday, Anna ^a   Voelkel, Norbert F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART STROKE VOLUME; HUMAN; LETTER; M MODE ECHOCARDIOGRAPHY; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARBAZOLES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PILOT PROJECTS; PROPANOLAMINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84902682715     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201311-2025LE     Document Type: Letter

References (14)

1. Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, Artaud-Macari E, Price LC, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis 2013;8:97.
2. Farber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant 2013;32:1114-1122.
3. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009;135:794-804.
4. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ. Mechanisms of right heart failure - a work in progress and a plea for failure prevention. Pulm Circ 2013;3:137-143.
5. So PP, Davies RA, Chandy G, Stewart D, Beanlands RS, Haddad H, Pugliese C, Mielniczuk LM. Usefulness of b-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 2012;109:1504-1509.
6. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652-660.
7. Drake JI, Gomez-Arroyo J, Dumur CI, Kraskauskas D, Natarajan R, Bogaard HJ, Fawcett P, Voelkel NF. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional pro file in experimental pulmonary hypertension. Physiol Genom 2013;45:449-461.
8. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol 1998;81:247-250. (Pubitemid 28057216)
9. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006;113:977-985. (Pubitemid 43879473)
10. Horikawa YT, Panneerselvam M, Kawaraguchi Y, Tsutsumi YM, Ali SS, Balijepalli RC, Murray F, Head BP, Niesman IR, Rieg T, et al. Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic peptide expression and signaling. J Am Coll Cardiol 2011;57:2273-2283.
11. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;58:2511-2519.
12. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006;130:120-126. (Pubitemid 43049842)
13. Peacock A, Ross K. Pulmonary hypertension: a contraindication to the use of β-adrenoceptor blocking agents. Thorax 2010;65:454-455.
14. Ohta Y, Watanabe K, Nakazawa M, Yamamoto T, Ma M, Fuse K, Ito M, Hirono S, Tanabe T, Hanawa H, et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 2000;36:S19-S23. (Pubitemid 32150659)